Business
4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting
EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of
About this update from 4d Molecular Therapeutics, Inc.
[{"type":"text","content":"EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced a late-breaking presentation of preliminary clinical data from the on-going 4D-125 Phase 1/2 trial in patients with X-Linked Retinitis Pigmentosa (XLRP) will be presented at the upcoming Annual Society of Retina Specialists Annual Meeting (ASRS) 2021 that will take place in San Antonio, TX on October 8-12, 2021. Details of the ASRS presentation are as follows: Title: Phase 1/2 Clinical Trial of Intravitreal 4D-125 AAV Gene Therapy in Patients with Advanced XLRP: Interim Safety & Preliminary Activity Speaker: Dr. Cagri G. Besirli M.D., Ph.D, Kellogg Eye Center, University of Michigan Session: Surgical Techniques & Maneuvers Symposium (Late Breaker Acceptance) Date and Time: Sunday, October 10, 2:56 p.m. CDT The presentation will be available for viewing by registered participants during the conference via the ASRS mobile meeting website on October 10, 2021. About the 4D-125 Phase 1/2 Clinical Trial 4DMT is currently enrolling patients in an on-going Phase 1/2 dose-escalation and dose-expansion clinical trial assessing intravitreal 4D-125, 4DMT’s targeted and evolved R100-based product candidate for XLRP. The study employs a standard 3+3 dose-escalation design, followed by dose expansion. Patients are enrolled in one of two dose cohorts: 3E11 vg/eye and 1E12 vg/eye. The dose expansion phase of the study is enrolling patients at the 1E12 vg/eye dose. The primary objectives of this trial are to evaluate the safety and maximum tolerated dose of 4D-125. Secondary endpoints include assessments of clinical activity, including both visual field function and anatomical endpoints. About XLRP XLRP is a rare inherited X-linked recessive genetic disorder that causes progressive vision loss and blindness in boys and young men. There are currently no approved therapies for XLRP. Seventy percent of cases are caused by mutations in the retinitis pigmentosa GTPase regulator (“RPGR”) gene. The estimated worldwide prevalence of XLRP due to RPGR variants is approximately one in 25,600 people, which represents approximately 24,000 patients in the United States, and France, Germany, Italy, Spain and the United Kingdom (together, EU-5). It ...